Posts

Showing posts with the label Dow

PreMarket Prep Stock Of The Day: Apple

Image
  Benzinga's  PreMarket Prep  airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. On any given day, the show will cover at least 20 stocks determined by co-hosts Joel Elconin and Dennis Dick along with producer Spencer Israel. Good news is good news, sometimes bad news is good news, and old news can be good news. The last part of the statement above applies to  Apple Inc. (NASDAQ: AAPL ), which is the PreMarket Prep Stock Of The Day. Six Years In The Making:  Project Titan has been in existence since 2014. Several of the company’s employees and a substantial amount of the companies resources have been devoted to the effort. But over the years for a variety of different reasons, Apple hasn't produced a car. In June 2017, Apple CEO Tim Cook teased shareholders when he provided an update on t

Moderna, Pfizer Testing Coronavirus Vaccine Against New Strain

Image
  Even with the relief brought by the conditional approval of two coronavirus vaccines, a more virulent and contagious variant of the virus in the U.K. has emerged.   Pfizer Inc.  (NYSE: PFE ), with its German partner  BioNTech SE – ADR  (NASDAQ: BNTX ), and  Moderna Inc  (NASDAQ: MRNA ) are the two companies that have received  approval  for emergency use of their respective investigational vaccines.  Now the question is whether their vaccines would work against the new strain in the U.K.  BioNTech Says It Could Tweak In 6 Weeks:  BioNTech expressed confidence that it could produce a vaccine to take on new variants of SARS-CoV-2 within six weeks, the German company's CEO Ugur Sahin reportedly told the  Financial Times. Related Link:  Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst  It would take two weeks to prove in a lab whether BNT162b2 – Pfizer-BioNTech's vaccine candidate would work effectively on the new strain, Sahin reportedly said. Even if it doe

LIVE MARKETS-Consumer confidence, home sales, GDP: The winter of our discontent

Image
  * Dow, S&P red; Nasdaq advances * Comm svcs weakest S&P sector; tech leads gainers * STOXX 600 up ~1% * Dollar up; gold, NYMEX crude down * US 10-Year Treasury yield 0.93%  Dec 22 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com   CONSUMER CONFIDENCE, HOME SALES, GDP: THE WINTER OF OUR DISCONTENT (1105 EST/1605 GMT) Data this month, last month and last quarter were released on Tuesday, providing a portrait in triptych of a pandemic battered economy limping toward the finish line of an exceptionally challenging year.   Consumer optimism unexpectedly soured this month, according to the Conference Board's consumer confidence index . The index fell to a reading of 88.6 from November's downwardly-revised 92.9 and well below the 97 consensus. While the 'expectations' component edged higher, this gain was more than offset by surging pessimism about t

Goldman Unit Makes New Push Into Real Estate with Stake in Sale-Leaseback Firm

Image
  DJ Goldman Unit Makes New Push Into Real Estate with Stake in Sale-Leaseback Firm   By Peter Grant A Goldman Sachs Group Inc. unit that buys stakes in alternative investment managers has made its latest push into the real-estate industry by investing in a firm that acquires stores, warehouses and other properties from big companies and then leases them back.  The unit, Petershill, in November purchased a minority stake in Oak Street Real Estate Capital LLC, which has raised over $4 billion since launching in 2009. Oak Street's funds have purchased hundreds of stores, warehouses and office buildings sold and leased back by companies such as Walgreens Boots Alliance Inc. and Big Lots Inc.  The size of the stake and the price paid by Goldman weren't disclosed, but the deal valued Oak Street at $2 billion, according to people familiar with the matter.  Since Petershill was founded in 2007, it has invested over $8 billion for stakes in more than 32 investment managers. Other real-

UPDATE: Dow slips to start Tuesday trade as investors mull Congress passing COVID aid package

Image
  MW UPDATE: Dow slips to start Tuesday trade as investors mull Congress passing COVID aid package   By Mark DeCambre  U.S. stock indexes kicked off trade mostly slightly lower Tuesday, after a volatile session Monday, amid worries about a new strain of COVID-19 in the U.K., and fresh lockdowns in some countries, even though Washington lawmakers hurried through a $900 billion coronavirus aid package for households and businesses, culminating months of tense negotiations.  On Monday (https://www.marketwatch.com/story/dow-set-to-sink-500-points-as-new-viral-strain-overshadows-fresh-coronavirus-aid-11608552060?mod=market-snapshot), markets finished mostly lower but not before a major comeback:  Markets were under a little pressure to start Tuesday's trading action but sentiment was more upbeat than in the previous session that had been framed by uncertainty about a new strain of coronavirus rampant in the U.K.  Investors were attempting to draw some optimism from the passage of a coro

Drugmakers rush to test whether vaccines stop coronavirus variant

Image
  By John Miller and Patricia Weiss ZURICH/FRANKFURT Dec 22 (Reuters) - Drug makers including BioNTech and Moderna are scrambling to test their COVID-19 vaccines against the new fast-spreading variant of the virus that is raging in Britain, the latest challenge in the breakneck race to curb the pandemic.   Ugur Sahin, chief executive of Germany's BioNTech , which with partner Pfizer took less than a year to get a vaccine approved, said on Tuesday he needs another two weeks to know if his shot can stop the mutant variant of the virus. Moderna expects immunity from its vaccine to protect against the variant and is performing more tests in coming weeks to confirm, the company said in a statement to CNN. Moderna did not immediately respond to Reuters' requests for comment.   The mutation known as the B.1.1.7 lineage may be up to 70% more infectious and more of a concern for children. It has sown chaos in Britain, prompting a wave of travel bans that are disrupting trade with Europe